The Burden of Multiple Myeloma in the Gulf Region
Author(s)
Farghaly M1, Fasseeh A2, Korra N3, Abd-El Aziz A3, Al dallal S4, Badr M5, Alblooshi S6, Elkonaissi I7, Alyaseen H8, Pandita R9, Ismail HA10, Hamad A11, Sabbah H12, Aljedai A13, Al-Mudaiheem H14, Alhejazi A15, Alabdulkarim H16, Saeed A17, Alotaibi G18, Al Farsi K19, Al Lamki M20, Al Qassabi A21, Emara S22, Abaza S23, Kalo Z24
1Dubai Health Authority, Dubai, Dubai, United Arab Emirates, 21) Faculty of Pharmacy Alexandria University 2) Syreon Middle East, Alexandria, Egypt, 3Syreon Middle East, Alexandria, Egypt, 4Emirates Medical Association, dubai, United Arab Emirates, 5Next Care Medical Insurance, Dubai, Dubai, United Arab Emirates, 6Tawam Hospital, Al Ain, Al Ain, United Arab Emirates, 7Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates, 8Dubai Health Authority Hospital, Dubai, Dubai, United Arab Emirates, 9Kuwait Cancer Control Centre, Shuwaikh, Kuwait, 10Kuwait Cancer Control Centre, Kuwait City, Kuwait, 11Hamad Medical Corporation, Doha, DA, Qatar, 12National Center for Cancer Care & Research, Doha, Qatar, Doha, Doha, Qatar, 131) Ministry of Health Riyadh, Saudi Arabia 2) Colleges of Pharmacy and Medicine, Alfaisal University, Riyadh, Saudi Arabia, Riyadh, Riyadh, Saudi Arabia, 14Ministry of Health, Riyadh, Saudi Arabia, 15Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia, 16King Abdulaziz Medical City - National Guard Health Affairs, Riyadh, Saudi Arabia, 17National Guard Hospital, Jeddah, Jeddah, Saudi Arabia, 18King Saud University Hospital, Riyadh, Riyadh, Saudi Arabia, 19Sultan Qaboos University Hospital, Muscat, Oman, 201) Royal Hospital, Muscat, Oman 2) Ministry of Health, Muscat, Oman, Muscat, Muscat, Oman, 2120. Head of Medical Supplies, Ministry of Health, Muscat, Oman, Muscat, Muscat, Oman, 22Johnson & Johnson, Dubai, Dubai, United Arab Emirates, 23Syreon Middle East, Cairo, C, Egypt, 241. Semmelweis University, Center for Health Technology Assessment; 2. Syreon Research Institute, Budapest, PE, Hungary
Presentation Documents
OBJECTIVES: Multiple myeloma (MM) represents – globally- 1%-2% of all cancers and around 10% of hematologic malignancies. Furthermore, MM imposes a significant economic burden along with substantial morbidity and mortality. Despite extensive global studies on MM, its burden in the Gulf region remains underexplored. This research aims to estimate the economic, humanistic, and clinical burden of MM in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, and Oman.
METHODS: This study evaluates the burden of MM within the Gulf region through a bottom-up approach, beginning with an estimation of the burden per patient and then multiplying it by the patient numbers in each country. We used a combination of secondary (literature review) and primary sources (subject-matter expert questionnaires) which were followed by a series of validation meetings to confirm the accuracy of the findings. To thoroughly examine the disease's impact, we categorized MM patients based on their eligibility for stem cell transplant, disease status, and risk level (newly diagnosed, relapsed/refractory, or undergoing maintenance therapy (high risk, intermediate-low risk)).
RESULTS: The weighted average annual direct cost per patient ranged from 125 to 372 thousand USD across all countries, with relapsed refractory patients incurring the highest individual costs. Furthermore, the indirect costs accounted for less than 10% of the total economic burden. The humanistic burden, quantified by disability-adjusted life years, averaged 7.69 per patient across all countries, with relapsed refractory transplant-ineligible patients suffering the most (8.29). The most common complications were anemia (54%), bone pain (51%), and microbial infections (39%).
CONCLUSIONS: MM represents a substantial burden in the Gulf region. Moreover, there is a huge unmet medical need, particularly among patients with relapsed refractory conditions. This underscores the need for healthcare policies and targeted resource allocation specifically tailored to the needs of MM patients in these countries.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EE178
Topic
Economic Evaluation
Disease
Oncology, Rare & Orphan Diseases